1509899-60-8

Basic information

• Product Name: 1-(7-BROMOQUINOLIN-2-YL)ETHANONE
• Synonyms: 1-(7-BROMOQUINOLIN-2-YL)ETHANONE
• CAS NO: 1509899-60-8
• Molecular Formula: C11H8BrNO
• Molecular Weight: 250.09
• Mol File: 1509899-60-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 351.4±22.0 °C(Predicted)
• Appearance: /
• Density: 1.520±0.06 g/cm3(Predicted)
• PKA: 0.87±0.50(Predicted)
• CAS DataBase Reference: 1-(7-BROMOQUINOLIN-2-YL)ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(7-BROMOQUINOLIN-2-YL)ETHANONE(1509899-60-8)
• EPA Substance Registry System: 1-(7-BROMOQUINOLIN-2-YL)ETHANONE(1509899-60-8)

Safety Data

• Hazardous Substances Data: 1509899-60-8(Hazardous Substances Data)

Usage

Appearance

Pale yellow solid

Usage

Building block in organic synthesis

Chemical Family

Quinolines (heterocyclic aromatic compounds with a benzene ring fused to a pyrimidine ring)

Potential Applications

a. Pharmaceutical research and drug development
b. Production of dyes and pigments
c. Other organic compounds

Unique Structure

Benzene ring fused to a pyrimidine ring with a bromine atom at the 7th position and an ethanone group attached to the 1st position

Reactivity

Versatile and valuable for a wide range of synthetic applications

Upstream product

• 99455-15-9 7-bromo-2-chloro-quinoline 
• 97674-02-7 tributyl(1-ethoxyvinyl)stannane 

Downstream Products

• 1509899-61-9 (R)-1-(7-bromoquinolin-2-yl)ethan-1-ol 

Relevant articles and documents

Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle

Cyclophilins are a family of peptidyl-prolyl isomerases that are implicated in a wide range of diseases including hepatitis C. Our aim was to discover through total synthesis an orally bioavailable, non-immunosuppressive cyclophilin (Cyp) inhibitor with potent anti-hepatitis C virus (HCV) activity that could serve as part of an all oral antiviral combination therapy. An initial lead 2 derived from the sanglifehrin A macrocycle was optimized using structure based design to produce a potent and orally bioavailable inhibitor 3. The macrocycle ring size was reduced by one atom, and an internal hydrogen bond drove improved permeability and drug-like properties. 3 demonstrates potent Cyp inhibition (Kd = 5 nM), potent anti-HCV 2a activity (EC50 = 98 nM), and high oral bioavailability in rat (100%) and dog (55%). The synthetic accessibility and properties of 3 support its potential as an anti-HCV agent and for interrogating the role of Cyp inhibition in a variety of diseases.

MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES

Provided are compounds of Formula I and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.